Literature DB >> 16413018

PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.

De-Hua Yu1, Wufang Fan, Guohong Liu, Vivian Nguy, Jon E Chatterton, Shilong Long, Ning Ke, Bernd Meyhack, Adrian Bruengger, Arndt Brachat, Flossie Wong-Staal, Qi-Xiang Li.   

Abstract

HeLaHF is a non-transformed revertant of HeLa cells, likely resulting from the activation of a putative tumor suppressor(s). p53 protein was stabilized in this revertant and reactivated for certain transactivation functions. Although p53 stabilization has not conclusively been linked to the reversion, it is clear that the genes in p53 pathway are involved. The present study confirms the direct role of p53 in HeLaHF reversion by demonstrating that RNAi-mediated p53 silencing partially restores anchorage-independent growth potential of the revertant through the suppression of anoikis. In addition, we identified a novel gene, named PHTS, with putative tumor suppressor properties, and showed that this gene is also involved in HeLaHF reversion independently of the p53 pathway. Expression profiling revealed that PHTS is one of the genes that is up-regulated in HeLaHF but not in HeLa. It encodes a putative protein with CD59-like domains. RNAi-mediated PHTS silencing resulted in the partial restoration of transformation (anchorage-independent growth) in HeLaHF cells, similar to that of p53 gene silencing, implying its tumor suppressor effect. However, the observed increased transformation potential by PHTS silencing appears to be due to an increased anchorage-independent proliferation rate rather than suppression of anoikis, unlike the effect of p53 silencing. p53 silencing did not affect PHTS gene expression, and vice versa, suggesting PHTS may function in a new and p53-independent tumor suppressor pathway. Furthermore, over-expression of PHTS in different cancer cell lines, in addition to HeLa, reduces cell growth likely via induced apoptosis, confirming the broad PHTS tumor suppressor properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413018     DOI: 10.1016/j.yexcr.2005.12.006

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  4 in total

Review 1.  Organization, evolution and functions of the human and mouse Ly6/uPAR family genes.

Authors:  Chelsea L Loughner; Elspeth A Bruford; Monica S McAndrews; Emili E Delp; Sudha Swamynathan; Shivalingappa K Swamynathan
Journal:  Hum Genomics       Date:  2016-04-21       Impact factor: 4.639

2.  Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.

Authors:  De-Hua Yu; James Macdonald; Guohong Liu; Amy S Lee; Mimi Ly; Timothy Davis; Ning Ke; Demin Zhou; Flossie Wong-Staal; Qi-Xiang Li
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

Review 3.  Characterization and function of human Ly-6/uPAR molecules.

Authors:  Hyun Kyung Kong; Jong Hoon Park
Journal:  BMB Rep       Date:  2012-11       Impact factor: 4.778

4.  ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.

Authors:  Yunhao Chen; Yanchun Zhao; Junru Chen; Chuanhui Peng; Yanpeng Zhang; Rongliang Tong; Qiyang Cheng; Beng Yang; Xiaode Feng; Yuejie Lu; Haiyang Xie; Lin Zhou; Jian Wu; Shusen Zheng
Journal:  Mol Cancer       Date:  2020-08-10       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.